exendin-4(1-32)K-capric acid

Exendin-4(1–32)K-capric acid is a modified peptide drug derived from exendin-4, a glucagon-like peptide 1 receptor (GLP‑1R) agonist. In this analog, the C-terminal Trp-cage of exendin‑4 is replaced with a capric acid (C10 fatty acid)-conjugated lysine at position 32. This modification enhances its pharmacokinetic properties by increasing binding to serum albumin and prolonging half-life compared to native exendin‑4[4]. Mechanistically, it acts as an agonist of the GLP‑1 receptor and suppresses food intake via activation of arcuate pro-opiomelanocortin (POMC) neurons in the hypothalamus through a protein kinase A-dependent pathway that closes ATP-sensitive potassium channels[1]. Preclinical studies show improved glucose regulation and body weight reduction in diabetic mice compared to unmodified exendin‑4[4]. The drug has been investigated for potential use in obesity and type 2 diabetes.

Other names

exendin-4(1–32)K-capric acidEx-4cEx4cEx 4c